No. 34 of Session 2002-03, dated 12 June 2003
THE SCIENTIFIC RESPONSE TO TERRORISM
FIFTH EVIDENCE SESSION
Monday 16 June 4.30pm
HEALTH AND SAFETY
Health and Safety Executive
Nick Starling, Co-Director, Safety Policy Directorate
Dr Paul Davies, Chief Scientist and Director, Corporate Science and Analytical Services Directorate
For further information, please ring the Committee staff on 020 7219 2793/4, or refer to the Committee Office Information Line on 020 7219 2033.
Previous press notices and publications are available on our website:
Notes for those wishing to attend a public meeting of the Committee
Members of the public wishing to attend should present themselves at St Stephen's Entrance, or Portcullis House if appropriate, where they will be directed through security and to the appropriate Committee Room. It is advisable to allow about 15 minutes for this. It is possible for the Committee Room designated for the hearing to change at short notice, but such room changes will be clearly indicated. Please ensure that mobile phones and pagers are turned off before entering the Committee Room. Under no circumstances should members of the public address the Committee while in session. It is not possible for seats to be reserved in the Committee Room but every effort is made to ensure sufficient seating. Standing in Committee Rooms is permitted at the discretion of the Chairman. Those attending meetings are asked to remain silent throughout.
Notes for Editors
Under the terms of Standing Order No. 152 the Committee is empowered to examine the 'expenditure, policy and administration of the Office of Science and Technology and its associated public bodies'. The Committee was appointed on 12 November 2001.
The Committee announced their inquiry into The Scientific Response to Terrorism on 19 December 2002, see Press Notice No. 8 of Session 2002-03.
The first session of evidence was held on 5 March with representatives of the constituent parts of the new Health Protection Agency, the BMA, the Royal College of GPs, the British Infection Society and Royal College of Physicians, NHS Trusts and the Ambulance Service. The second session was held on 2 April with Acambis, PowderJect, the ABPI and GlaxoSmithKline; Department of Health, Defense Science and Technology Laboratory and the Police Scientific Development Branch. The third session focused on the regulation of academic research and an ethical code of conduct. It was held on 14 May with the Academy of Medical Sciences, Research Council UK, the Royal Society and the UK Biosciences Federation. The fourth session was held on Wednesday 21 May with Foods Standards Agency, Thames Water and Tesco plc. Final evidence sessions will focus on:
-Strategy and policy: Ministers (30 June)
Details of witnesses to be announced.